Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138266 | 0.85 | ESRRG (0.43) | CCR2KDM4EALDH1A1SMN1; SMN2KDM1A | |
| SCHEMBL2458675 | 0.84 | CCR2 (0.47) | CCR2KDM4EALDH1A1SMN1; SMN2CCR3 | |
| SCHEMBL17556530 | 0.82 | CCR2 (0.44) | CCR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3138183 | 0.81 | CCR2 (0.47) | CCR2 | |
| SCHEMBL15015557 | 0.78 | ALDH1A1 (0.52) | CCR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13753892 | 0.78 | NOS2 (0.43) | CCR2KDM4EALDH1A1 | |
| SCHEMBL7104333 | 0.76 | L3MBTL1 (0.48) | CCR2KDM4EALDH1A1 | |
| SCHEMBL2461017 | 0.73 | SIRT6 (0.46) | CCR2KDM4EALDH1A1 | |
| SCHEMBL3226426 | 0.73 | BRAF (0.45) | CCR2KDM4EALDH1A1 | |
| SCHEMBL13408851 | 0.73 | HPGD (0.52) | CCR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| EP-1861380-B1 | 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | ORGANON NV (NL) | 2010-07-07 | — | — | EP | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | AVPR2, AVPR1A, AVPR1B | CCR2 1973/4885KDM4E 2703/4885ALDH1A1 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.